Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 2/20 | 0.44 |
| ▸ | PBK | Q96KB5 | 2/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 8/20 | 0.40 |
| ▸ | JAK1 | P23458 | 8/20 | 0.40 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100483 | 0.79 | PRKCI (0.54) | AKT2PBKNUDT1PRKCIGSK3B | |
| Trifluoroacetic Acid SCHEMBL4082434 | 0.72 | PRKCI (0.46) | AKT2PBKNUDT1PRKCIGSK3B | |
| SCHEMBL13774669 | 0.70 | PRKCI (0.52) | AKT2PBKNUDT1PRKCIJAK2 | |
| SCHEMBL18599525 | 0.68 | PRKCI (0.51) | AKT2PBKNUDT1PRKCIGSK3B | |
| SCHEMBL100482 | 0.68 | JAK1 (0.45) | AKT2PBKNUDT1PRKCIJAK2 | |
| SCHEMBL18602143 | 0.67 | PRKCI (0.49) | AKT2PBKNUDT1PRKCIGSK3B | |
| SCHEMBL28055281 | 0.67 | PRKCI (0.46) | AKT2PBKNUDT1PRKCIJAK2 | |
| SCHEMBL4082436 | 0.66 | PRKCI (0.46) | AKT2PBKNUDT1PRKCIGSK3B | |
| SCHEMBL100939 | 0.66 | JAK2 (0.52) | AKT2NUDT1PRKCIJAK2JAK3 | |
| SCHEMBL29540619 | 0.66 | JAK2 (0.52) | AKT2NUDT1PRKCIJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933086-B2 | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933086-B2 | Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140018374-A1 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018374-A1 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors | INCYTE CORPORATION (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018374-A1 | Heteroaryl Substituted Pyrrolo[2,3-B]Pyridines And Pyrrolo[2,3-B]Pyrimidines As Janus Kinase Inhibitors | JAK3, JAK1, JAK2 | AKT2 1064/4885PBK 359/4885NUDT1 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.